In this conversation, Shawn Gremminger, a 340B program expert, shares why employers should pay attention to this crucial healthcare initiative. He explains how the program, designed for low-income Americans, unexpectedly impacts drug pricing for employers, leading to lost rebates and higher costs. Shawn dives into studies revealing market distortions caused by 340B entities and questions its effectiveness in assisting underserved communities. This episode emphasizes the need for employers to understand the financial risks associated with the 340B program.

Shawn Gremminger, a specialist in the 340B program, dives into its origins and evolution since its inception in 1992. He discusses the initial intentions of the program to help underserved communities, contrasting them with current outcomes. Gremminger raises critical questions about transparency and effectiveness, particularly regarding its impact on safety-net providers. The conversation highlights the financial strain on hospitals and the growing need for reform to ensure that 340B genuinely benefits those it was designed to help.